• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成瘾患者治疗中断的预测:成瘾治疗中断预测因子(PDAT)量表的开发与验证。

Prediction of therapeutic dropout in patients with addictions: Development and validation of the Predictors of Dropout from Addiction Treatment (PDAT) scale.

作者信息

Sirvent-Ruiz Carlos Miguel, Miranda María, Moral-Jiménez María de la Villa

机构信息

Research and Teaching Department, Fundación Instituto Spiral, Madrid, Spain.

Department of Psychology, University of Oviedo, Oviedo, Spain.

出版信息

PLoS One. 2025 Jun 27;20(6):e0326853. doi: 10.1371/journal.pone.0326853. eCollection 2025.

DOI:10.1371/journal.pone.0326853
PMID:40577266
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12204563/
Abstract

BACKGROUND

Withdrawal from addiction treatment is a frequent but difficult-to-predict contingency. We clarify and contextualize the concept of dropouts in addiction treatment, as well as the external and internal elements that most frequently lead to such dropouts. The main instruments used to measure dropout are summarized, after which a new tool, Predictors of Dropout from Addiction Treatment (PDAT) scale, is presented. The PDAT consists of four factors: 1) Motivation: desire to recover and to actively engage in current treatment; 2) Craving: longing for the use of substances and/or the substance addiction environment; 3) Problem awareness: level of insight, or degree of knowledge, and ability to objectify the problem and the disease, with the renunciations and limitations that this entails; and 4) Dysphoria: dyade inner restlessness - moodiness, i.e., emotional disturbance and depressive anticipation that precedes treatment withdrawal.

METHODS

The sample consisted of 243 addicted subjects in residential treatment, ranging in age from 18 to 63 years (average = 38.43, standard deviation = 10.95), who completed an initial 26-item PDAT questionnaire. The factor structure of the PDAT was determined by factor analysis. Mixed effects logistic regressions and receiver operating characteristics curve (ROC) analyses were applied to assess the predictive validity of the PDAT. Results: The 13-item PDAT showed adequate reliability and convergent and discriminant validity, with both the general scale and each of its factors having predictive validity 7 and 15 days after administration.

CONCLUSION

The scale is a useful instrument with proven clinical efficacy and brevity of application. In addition, its four factors are useful for targeting interventions based on the unbalanced factors.

摘要

背景

从成瘾治疗中退出是一种常见但难以预测的情况。我们阐明并将成瘾治疗中退出的概念置于具体情境中,以及最常导致此类退出的外部和内部因素。总结了用于衡量退出的主要工具,之后介绍了一种新工具——成瘾治疗退出预测因子(PDAT)量表。PDAT由四个因素组成:1)动机:康复的愿望以及积极参与当前治疗的意愿;2)渴望:对使用物质和/或物质成瘾环境的渴望;3)问题意识:洞察力水平、知识程度以及将问题和疾病客观化的能力,以及随之而来的放弃和限制;4)烦躁不安:内心不安与喜怒无常的二元组合,即治疗退出前的情绪困扰和抑郁预期。

方法

样本包括243名接受住院治疗的成瘾者,年龄在18至63岁之间(平均 = 38.43,标准差 = 10.95),他们完成了一份初始的26项PDAT问卷。通过因子分析确定PDAT的因子结构。应用混合效应逻辑回归和受试者工作特征曲线(ROC)分析来评估PDAT的预测效度。结果:13项PDAT显示出足够的信度、收敛效度和区分效度,量表及其各个因子在施测后7天和15天均具有预测效度。

结论

该量表是一种有用的工具,具有已证实的临床疗效和应用简便性。此外,其四个因素有助于基于不平衡因素进行有针对性的干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/801d/12204563/6ef75e2acefe/pone.0326853.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/801d/12204563/1a18caffc8d0/pone.0326853.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/801d/12204563/6ef75e2acefe/pone.0326853.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/801d/12204563/1a18caffc8d0/pone.0326853.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/801d/12204563/6ef75e2acefe/pone.0326853.g002.jpg

相似文献

1
Prediction of therapeutic dropout in patients with addictions: Development and validation of the Predictors of Dropout from Addiction Treatment (PDAT) scale.成瘾患者治疗中断的预测:成瘾治疗中断预测因子(PDAT)量表的开发与验证。
PLoS One. 2025 Jun 27;20(6):e0326853. doi: 10.1371/journal.pone.0326853. eCollection 2025.
2
Psychological therapies for treatment-resistant depression in adults.成人难治性抑郁症的心理治疗
Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2.
3
Pharmacological treatments in panic disorder in adults: a network meta-analysis.成人惊恐障碍的药物治疗:网络荟萃分析。
Cochrane Database Syst Rev. 2023 Nov 28;11(11):CD012729. doi: 10.1002/14651858.CD012729.pub3.
4
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
5
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Psychological and/or educational interventions for the prevention of depression in children and adolescents.预防儿童和青少年抑郁症的心理和/或教育干预措施。
Cochrane Database Syst Rev. 2004(1):CD003380. doi: 10.1002/14651858.CD003380.pub2.
8
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.创伤后应激障碍及共病物质使用障碍的心理治疗
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
9
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
10
Selegiline for Alzheimer's disease.司来吉兰用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2003(1):CD000442. doi: 10.1002/14651858.CD000442.

本文引用的文献

1
Retention in treatment and therapeutic adherence: How are these associated with therapeutic success? An analysis using real-world data.治疗中的保留和治疗依从性:这些与治疗成功有何关联?使用真实世界数据进行的分析。
Int J Methods Psychiatr Res. 2022 Dec;31(4):e1929. doi: 10.1002/mpr.1929. Epub 2022 Jun 28.
2
Association of Drug Cues and Craving With Drug Use and Relapse: A Systematic Review and Meta-analysis.药物线索和渴求与药物使用和复吸的关联:系统评价和荟萃分析。
JAMA Psychiatry. 2022 Jul 1;79(7):641-650. doi: 10.1001/jamapsychiatry.2022.1240.
3
Link Between Perception of Treatment Need and Craving Reports in Addiction.
成瘾中治疗需求认知与渴望报告之间的联系。
Front Psychiatry. 2022 Jan 31;12:790203. doi: 10.3389/fpsyt.2021.790203. eCollection 2021.
4
A matter of craving-An archeology of relapse prevention in Swedish addiction treatment.一种渴望的问题——瑞典成瘾治疗中复发预防的考古学。
Int J Drug Policy. 2022 Mar;101:103575. doi: 10.1016/j.drugpo.2021.103575. Epub 2022 Jan 3.
5
Barriers to retention in substance use treatment: Validation of a new, theory-based scale.物质使用治疗中保留的障碍:一种新的、基于理论的量表的验证。
J Subst Abuse Treat. 2021 Dec;131:108422. doi: 10.1016/j.jsat.2021.108422. Epub 2021 Apr 21.
6
Predictors of and reasons for early discharge from inpatient withdrawal management settings: A scoping review.住院脱瘾管理机构早期出院的预测因素及原因:一项范围综述
Drug Alcohol Rev. 2022 Jan;41(1):62-77. doi: 10.1111/dar.13311. Epub 2021 May 27.
7
Examining the Relationship of Personality Functioning and Treatment Completion in Substance Misuse Treatment.探究物质滥用治疗中人格功能与治疗完成情况的关系。
Subst Abuse. 2020 Oct 6;14:1178221820951777. doi: 10.1177/1178221820951777. eCollection 2020.
8
Insight in substance use disorder: A systematic review of the literature.物质使用障碍的洞察:文献系统综述
Addict Behav. 2020 Dec;111:106549. doi: 10.1016/j.addbeh.2020.106549. Epub 2020 Jul 13.
9
Retention of patients in opioid substitution treatment: A systematic review.阿片类药物替代治疗中患者的保留情况:系统评价。
PLoS One. 2020 May 14;15(5):e0232086. doi: 10.1371/journal.pone.0232086. eCollection 2020.
10
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.青少年和年轻成年人阿片类药物使用障碍药物的坚持和保留。
Epidemiol Rev. 2020 Jan 31;42(1):41-56. doi: 10.1093/epirev/mxaa001.